Deliver Your News to the World

LogicInk and Contakt World Partner to Accelerate Development of COVID-19 Biosensor Sticker

The non-invasive, saliva-based COVID-19 viral RNA biosensor sticker could make it feasible to be applied to the entire world population, at home, frequently

San Francisco, CA – WEBWIRE

LogicInk, the creator of non-invasive, tattoo-like wearables – called Signals – that help consumers track and measure their wellbeing, and Contakt World Technologies Corp. (“Contakt World”), a technology company modernizing the contact tracing process, today announced they have signed a Memorandum of Understanding (MOU) to accelerate the development of LogicInk’s non-invasive, biosensor sticker for vector-borne diseases such as COVID-19.

Leveraging its patent-pending wearable wellbeing platform, LogicInk’s new Signal would allow for entire populations to self-administer and interpret results to screen the presence of SARS-CoV-2 RNA (COVID-19) simply by identifying an appropriate color combination. Consumers simply use a special applicator to deposit saliva onto the biosensor then place the sticker on a surface to wait for the results. The test can be repeated as many times as needed, without interaction with medical personnel. Because LogicInk Signals can be efficiently mass-produced and are easy to apply, and do not require any testing cartridges or lateral flow strips, it is financially and logistically feasible to test entire populations for COVID-19. The sensitivity and specificity of the test is designed to be comparable to the gold standard of PCR-based solutions and without requiring a centralized laboratory to be involved. 

“Developing this kind of biosensor Signal has long been on our product roadmap but the speed, breadth, and global impact of COVID-19 compelled us to act now,” said Carlos Olguin, founder & CEO of LogicInk. “This is a unique moment in our lifetime, as humans and for LogicInk the company, and we felt an immediate responsibility to focus our efforts on developing an intuitive, scalable, rapid, and reliable test for COVID-19 and any future pandemics. Imagine every household in the world has a small box of biosensor Signals, similar to a box of band-aids that can be easily used whenever and as frequently as needed, effectively giving us the ability to detect a vector-borne disease as soon as it manifests. This is the world that LogicInk is building toward.”

LogicInk’s biosensor focuses on signaling early detection, which has been shown to stem the outbreak and transmission of all viruses, including SARS-CoV-2 (COVID-19). Evidence from the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) suggests that COVID-19 can be detected in carriers 1-3 days before their symptoms appear. Presymptomatic and asymptomatic carriers can also unknowingly transmit the virus, making the need for ubiquitous, easily accessible testing critically important. 

Enter your email here to be the first to know when the Signals are available.

Despite all the advances in technology, the COVID-19 pandemic has demonstrated that we are very much still in the dark ages in terms of effective response to major health crises. As a result, countries either shut down completely, or try to open back up to soon (and unsafely), damaging the economy and a host of other consequences. LogicInk’s new Signal is effectively a business and economic enabler that lets employees and customers come back to businesses and allow for safe re-opening. 

Communities are reliant upon the accuracy, efficiency, and execution of contact tracing in effectively battling COVID-19, or any health crisis. Real-time testing linked with contact tracing is critical in situations where immediate decision-making is necessary, such as screening patients for hospital admission, or stopping transmission chains through quarantine and other health agency protocols. Contakt World is modernizing contact tracing and ethical surveillance by providing a singular platform to link health departments with community members and locations, while leveraging a unique data structure that preserves personal information and protects health information from unauthorized use. 

“We are excited to partner with LogicInk to provide these accessible, simple to use COVID-19 biosensor Signals to people right in the comfort of their own homes once LogicInk can mass produce them,” said Justin Beck, founder & CEO of Contakt World. “By deliberately making these kits accessible and reaching people where they are, we are working to eliminate healthcare disparities and helping those who might not otherwise have access to COVID-19 testing. Contakt World’s direct-to-consumer and direct-to-business/institution screening kits using LogicInk’s technology could be critical in helping our most vulnerable populations battle the health inequities exacerbated by COVID-19. We hope to make the kits affordable for any household in 2021, seamlessly integrated with our apps and the Contakt World Platform to immediately enable private tracing for the COVID-19 virus and other contagions.”

The development of LogicInk’s new biosensor Signal builds on the company’s momentum to date, growth of its original LogicInk Suncare Signals, and continued partnerships with global Fortune 100 and 200 CPG brands. LogicInk plans to continue to support its global B2B partners with existing work on Signals for hydration and pollution and will put all effort and force behind the completion of the COVID-19 biosensor sticker. 

See how the Suncare Signals work on The World According to Jeff Goldblum on Disney+.

LogicInk’s scientific team and advisors include Chief Scientist Hendrik Dietz, PhD who ranks among the world’s leading researchers in DNA nanotechnology; Harvard Medical School genomics pioneer George Church, PhD; Larry Weiss, Founder and CSO at Symbiome; Lee Cronin, PhD, who investigates the digitization of chemistry and the creation of artificial life at the University of Glasgow; and David Hanzel, PhD, former Vice President at Pacific Biosciences, and more recently CSO at Naked Biome.

About LogicInk

LogicInk is the creator of non-invasive tattoo-like biosensor Signals that help consumers track and measure their bodies and the environments around them. We envision a future where LogicInk Signals seamlessly integrate into daily life, allowing us to see the invisible and take action to live a longer and healthier life. Powered by programmable chemistry and biology, LogicInk Signals in production and in R&D display a real-time readout on a person’s accumulation of UV exposure, pollution, hydration levels, alcohol consumption awareness (NIH funded), and more. Backed by a team of world renowned physicists, chemists, designers, computer scientists, synthetic biologists, and physicians, LogicInk is headquartered in San Francisco, with partners and collaborators located around the world. For more information, visit

About Contakt World

Contakt World is a data technology company innovating the contact tracing process, with the goal of becoming the most trustworthy, accessible and scalable contact tracing and health surveillance system globally. Contakt World combines aggressive research and development, next-gen data integrations and strategic health partnerships to empower and build mutual trust within communities, contributing towards health equity for users around the world. For more information, please visit the Company’s website at Contakt LLC of California is a subsidiary of Contakt World Technologies Corp. in Vancouver, British Columbia, Canada. 


This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the possibility that LogicInk’s biosensor sticker may not be effective at detecting vector-borne diseases such as COVID-19. At this time, LogicInk and Contakt World have only entered into a MOU to develop LogicInk’s biosensor sticker for vector-borne diseases such as COVID-19, and there can be no assurance that the companies will enter into a definitive agreement for the continued development and commercialization of the product.  LogicInk’s bionsensor stickers have not been approved by the FDA and they have not been demonstrated to be effective at detecting the SARS-CoV-2 (COVID-19) virus at this time. Further, it is possible that LogicInk and Contakt World may make the strategic decision to discontinue development of LogicInk’s biosensor stickers for vector-borne diseases such as COVID-19. As a result, the bionsensor stickers may never be successfully developed and/or commercialized for COVID-19 detection. In addition, LogicInk may be unable to sufficiently scale up the production of its biosensor stickers in the currently anticipated timelines, or may be unable to meet future supply needs. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements contained herein. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to LogicInk and Contakt World, and each company assumes no obligation to update any such forward-looking statements


 Covid Test
 Contact Tracing

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.